Real-World Treatment Patterns and Survival Outcomes in Metastatic Triple Negative Breast Cancer: Immunotherapy- Versus Anti-Angiogenic Therapy-Combined-With-Chemotherapy

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-09-16 DOI:10.1002/cam4.71164

Yingzhe Wang, Song Wu, Jianbin Li, Yang Yuan, Li Bian, Shaohua Zhang, Tao Wang, Zefei Jiang

{"title":"Real-World Treatment Patterns and Survival Outcomes in Metastatic Triple Negative Breast Cancer: Immunotherapy- Versus Anti-Angiogenic Therapy-Combined-With-Chemotherapy","authors":"Yingzhe Wang, Song Wu, Jianbin Li, Yang Yuan, Li Bian, Shaohua Zhang, Tao Wang, Zefei Jiang","doi":"10.1002/cam4.71164","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>There is limited clinical evidence comparing different chemotherapy-based combination therapies. This study aimed to evaluate and compare the efficacy and safety of chemotherapy combined with immunotherapy versus chemotherapy combined with anti-angiogenic therapy in the treatment of metastatic triple-negative breast cancer (TNBC).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study included patients with metastatic TNBC who received either anti-PD-1 monoclonal antibody or bevacizumab in combination with chemotherapy. The primary endpoint was progression-free survival (PFS); the secondary endpoints included overall response rate (ORR), clinical benefit rate (CBR), and safety.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Between October 2018 and June 2024, 130 eligible patients were enrolled. Of these, 60 patients received chemotherapy combined with anti-PD-1 monoclonal antibody, and 70 patients received chemotherapy combined with bevacizumab. The median PFS was 5.9 months (95% CI: 4.3–8.7) in the immunotherapy group, compared to 3.0 months (95% CI: 2.2–4.7) in the bevacizumab group (hazard ratio [HR] = 0.42, 95% confidence interval [CI] 0.28–0.62, <i>p</i> < 0.0001). The ORR rates were 55% in the immunotherapy group and 27.1% in the bevacizumab group (<i>p</i> = 0.001). The CBR rates were 43.3% and 22.9%, respectively (<i>p</i> = 0.013). The overall incidence of adverse events was comparable between the two groups.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In the treatment of metastatic TNBC, chemotherapy combined with immunotherapy offers significant survival advantages over chemotherapy combined with bevacizumab.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439273/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71164","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

There is limited clinical evidence comparing different chemotherapy-based combination therapies. This study aimed to evaluate and compare the efficacy and safety of chemotherapy combined with immunotherapy versus chemotherapy combined with anti-angiogenic therapy in the treatment of metastatic triple-negative breast cancer (TNBC).

Methods

This study included patients with metastatic TNBC who received either anti-PD-1 monoclonal antibody or bevacizumab in combination with chemotherapy. The primary endpoint was progression-free survival (PFS); the secondary endpoints included overall response rate (ORR), clinical benefit rate (CBR), and safety.

Results

Between October 2018 and June 2024, 130 eligible patients were enrolled. Of these, 60 patients received chemotherapy combined with anti-PD-1 monoclonal antibody, and 70 patients received chemotherapy combined with bevacizumab. The median PFS was 5.9 months (95% CI: 4.3–8.7) in the immunotherapy group, compared to 3.0 months (95% CI: 2.2–4.7) in the bevacizumab group (hazard ratio [HR] = 0.42, 95% confidence interval [CI] 0.28–0.62, p < 0.0001). The ORR rates were 55% in the immunotherapy group and 27.1% in the bevacizumab group (p = 0.001). The CBR rates were 43.3% and 22.9%, respectively (p = 0.013). The overall incidence of adverse events was comparable between the two groups.

Conclusion

In the treatment of metastatic TNBC, chemotherapy combined with immunotherapy offers significant survival advantages over chemotherapy combined with bevacizumab.

Abstract Image

查看原文本刊更多论文

转移性三阴性乳腺癌的真实世界治疗模式和生存结果：免疫治疗与抗血管生成治疗联合化疗

目的：比较不同化疗联合疗法的临床证据有限。本研究旨在评价和比较化疗联合免疫治疗与化疗联合抗血管生成治疗治疗转移性三阴性乳腺癌（TNBC）的疗效和安全性。方法：本研究纳入了接受抗pd -1单克隆抗体或贝伐单抗联合化疗的转移性TNBC患者。主要终点是无进展生存期（PFS）；次要终点包括总缓解率（ORR）、临床获益率（CBR）和安全性。结果：2018年10月至2024年6月，纳入了130例符合条件的患者。其中60例患者联合抗pd -1单克隆抗体化疗，70例患者联合贝伐单抗化疗。免疫治疗组的中位PFS为5.9个月（95% CI: 4.3-8.7），而贝伐单抗组的中位PFS为3.0个月（95% CI: 2.2-4.7）（风险比[HR] = 0.42, 95%可信区间[CI] 0.28-0.62, p）结论：在转移性TNBC的治疗中，化疗联合免疫治疗比化疗联合贝伐单抗具有显著的生存优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.